Wilms Tumor Treatment Study - Phase III

Treatment for Very-Low and Standard-Risk Favorable Histology Wilms Tumor

Protocol Description

The goal of this Children's Oncology Group Phase III trial is to evaluate the overall and event-free survival of younger patients with newly diagnosed stage I-III Wilms tumor who will be given one of three courses of treatment dependant on the level of risk associated with the patient’s diagnosis. Treatment courses include kidney removal only (nephrectomy); nephrectomy followed by chemotherapy, or nephrectomy followed by chemotherapy including doxorubicin hydrochloride, and radiotherapy. Secondary goals include, among others, determining whether there are other characteristics of the tumor cells that might reveal why standard treatment does not eliminate tumor recurrence for stage III Wilms tumor patients.

Eligibility Criteria

Eligible candidates include patients under the age of 30 who have been newly diagnosed with Wilms tumor and which meet criteria related to tumor size and loss of heterozygosity (LOH), among others.
Males: Under age 30
Females: Under age 30

Treatment will vary depending on whether participants are enrolled in observational or chemotherapy portions of the study.
Visits: Requires hospitalization for sugery, with follow-up treatment dependent on disease diagnosis.
Duration: Those receiving chemotherapy will require 25 weeks of treatment. All participants’ health will be followed for 5 years.

Status: Open for Enrollment

Source of Support
Children’s Oncology Group (Study AREN0532)
National Cancer Institute

Additional Resources
Children’s Oncology Group CureSearch
Study Description at National Institutes of Health

Primary Investigator(s)

A. Kim Ritchey, MD

Contact Information

To get started, please contact:
A. Kim Ritchey, MD

Last Update
January 2, 2014
  • Increase/Decrease Text Size
  • Print This Page
Last Update
January 2, 2014